Tags:BioTechCenterInterestPlatform
OncoResponse is a clinical stage, privately held immuno-oncology biotech company developing cancer immunotherapies using clues from the immune systems of elite cancer responders. In a broad strategic alliance with MD Anderson Cancer Center, OncoResponse deploys a proprietary B-cell discovery platform to identify and develop novel therapeutics targeting the tumor microenvironment. The company’s lead candidate, OR2805, has entered clinical studies with a unique and transformative approach to the advancement of cancer therapeutics. OncoResponse is based in Seattle, Washington.
Total raised: $126.1M
Founded date: 2016

Investors 4

Funding Rounds 6

DateSeriesAmountInvestorsDeal News
31.03.2021Series C$40.6M-geekwire.c...
11.09.2018Series B$40M-geekwire.c...
09.03.2017Series A$22.5M-finsmes.co...
10.10.2016Series A$7M-finsmes.co...
29.05.2016Series A$12.5M-finsmes.co...
--$3.5MHelsinn In...helsinninv...

Mentions in press and media 23

DateTitleDescriptionCategoryAuthorSource
31.03.2021Seattle bi...Clifford Stocks. (OncoResponse...-Taylor Sop...geekwire.c...
31.03.2021Seattle bi...Clifford Stocks. (OncoResponse...-Taylor Sop...geekwire.c...
31.03.2021OncoRespon...- New capital will fund lead a...--marketscre...
18.06.2019Houston’s ...Houston is the most ethnically...--startupgen...
12.09.2018Term Sheet...REBOOT REPRESENTATION Good mo...--fortune.co...
11.09.2018OncoRespon...The company’s approach consist...--medcitynew...
11.09.2018OncoRespon... SEATTLE, WA, OncoResponse to...--vcnewsdail...
11.09.2018OncoRespon...OncoResponse, a Seattle, WA-ba...USA-finsmes.co...
11.09.2018OncoRespon...(Bigstock Photo) OncoResponse...-Clare McGr...geekwire.c...
11.09.2018Daily fund...Packet raises $25M to accelera...-Kristin Ka...vator.tv/n...
Show more